Jpmorgan Chase & CO Y M Abs Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 27,481 shares of YMAB stock, worth $408,642. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,481
Previous 31,168
11.83%
Holding current value
$408,642
Previous $506,000
34.58%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding YMAB
# of Institutions
101Shares Held
23.9MCall Options Held
19.4KPut Options Held
300-
Paradigm Biocapital Advisors LP New York, NY3.87MShares$57.6 Million1.89% of portfolio
-
Black Rock Inc. New York, NY2.94MShares$43.7 Million0.0% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.19MShares$32.6 Million1.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.96MShares$29.1 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X01.83MShares$27.2 Million0.13% of portfolio
About Y-mAbs Therapeutics, Inc.
- Ticker YMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,719,500
- Market Cap $650M
- Description
- Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...